Exelixis, Inc. (LON:0IJO)
42.83
+0.24 (0.56%)
At close: Feb 12, 2026
Exelixis Revenue
In the year 2025, Exelixis had annual revenue of $2.32B USD with 6.98% growth. Exelixis had revenue of $598.66M in the quarter ending December 31, 2025, with 5.63% growth.
Revenue
$2.32B
Revenue Growth
+6.98%
P/S Ratio
4.74
Revenue / Employee
$2.15M
Employees
1,077
Market Cap
8.17B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.32B | 151.43M | 6.98% |
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
| Dec 31, 2018 | 853.83M | 401.35M | 88.70% |
| Dec 31, 2017 | 452.48M | 261.02M | 136.34% |
| Dec 31, 2016 | 191.45M | 154.28M | 415.05% |
| Dec 31, 2015 | 37.17M | 12.06M | 48.03% |
| Dec 31, 2014 | 25.11M | -6.23M | -19.87% |
| Dec 31, 2013 | 31.34M | -16.11M | -33.96% |
| Dec 31, 2012 | 47.45M | -242.19M | -83.62% |
| Dec 31, 2011 | 289.64M | 104.59M | 56.52% |
| Dec 31, 2010 | 185.05M | 33.29M | 21.93% |
| Dec 31, 2009 | 151.76M | 33.90M | 28.76% |
| Dec 31, 2008 | 117.86M | 4.39M | 3.87% |
| Dec 31, 2007 | 113.47M | 14.80M | 15.00% |
| Dec 31, 2006 | 98.67M | 22.71M | 29.90% |
| Dec 31, 2005 | 75.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| CVS Group | 673.20M |
| Genus | 672.80M |
Exelixis News
- 9 hours ago - EXEL: HC Wainwright & Co. Raises Price Target, Maintains Buy Rating | EXEL Stock News - GuruFocus
- 1 day ago - EXEL Stock: Wells Fargo Raises Price Target to $35.00 | EXEL Stock News - GuruFocus
- 1 day ago - Exelixis, Inc. 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 1 day ago - Decoding Exelixis Inc (EXEL): A Strategic SWOT Insight - GuruFocus
- 1 day ago - Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus
- 1 day ago - Q4 2025 Exelixis Inc Earnings Call Transcript - GuruFocus
- 1 day ago - Exelixis (EXEL) Reports Strong Q4 2025 Earnings with Robust Growth - GuruFocus
- 1 day ago - Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch - Seeking Alpha